Macrogenics, Inc. shares rise 2.58% premarket after Johnson & Johnson's Alzheimer research progress and AstraZeneca's successful drug trial.

viernes, 5 de septiembre de 2025, 6:11 am ET1 min de lectura
MGNX--
Macrogenics, Inc. rose 2.58% in premarket trading. The news events provided do not directly relate to Macrogenics, Inc. Therefore, the cause of the stock's movement cannot be determined from the given information.

Macrogenics, Inc. shares rise 2.58% premarket after Johnson & Johnson's Alzheimer research progress and AstraZeneca's successful drug trial.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios